The timed-pregnant baboon animal model can be used for determining the role of soluble vascular endothelial growth factor receptors 1 and 2 during development

Journal of Medical Primatology

Volumn 36, Issue 6, 2007, Pages 370-374

  Santolaya Forgas, Joaquin ^a,b,d   Edwin, Samuel ^b   Zeiter, Katie ^b   Pitt, Adam ^b   Pineles, Beth ^b   Tarca, Adi L ^b   Espinoza, Jimmy ^b   Kusanovic, Juan Pedro ^b   Erez, Offer ^b   Wolf, Roman ^c   Romero, Roberto ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiogenesis; FLK1; FLT1; Placental vascularization; Vascular endothelial growth factor; VEGF receptors

Indexed keywords

VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CESAREAN SECTION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME IMMUNOASSAY; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; FEMALE; FETUS; FETUS BLOOD; MATERNAL BLOOD; NONHUMAN; PAPIO ANUBIS; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; UMBILICAL CORD BLOOD;

ANIMALS; FEMALE; FETAL BLOOD; HUMANS; IMMUNOASSAY; MODELS, ANIMAL; PAPIO ANUBIS; PREGNANCY; PREGNANCY, ANIMAL; REPRODUCIBILITY OF RESULTS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

ANIMALIA; PAPIO; PAPIO ANUBIS;

EID: 35748949297     PISSN: 00472565     EISSN: 16000684     Source Type: Journal    
DOI: 10.1111/j.1600-0684.2006.00205.x     Document Type: Article

References (30)

1. Albrecht ED, Robb VA, Pepe GJ: Regulation of placental vascular endothelial growth/permeability factor expression and angiogenesis by estrogen during early baboon pregnancy. J Clin Endocrinol Metab 2004; 89: 5803-9.
2. Barleon B, Reusch P, Totzke F, Herzog C, Keck C, Martiny-Baron G et al.: Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 2001; 4: 143-54.
3. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M et al.: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-9.
4. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J et al.: Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3-18.
5. Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN et al.: A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998; 59: 1540-8.
6. Downs KM: Florence Sabin and the mechanism of blood vessel lumenization during vasculogenesis. Microcirculation 2003; 10: 5-25.
7. Ferrara N: Vascular endotheliaB growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
8. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
9. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
10. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G et al.: VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417: 954-8.
11. Geva E, Ginzinger DG, Zaloudek CJ, Moore DH, Byrne A, Jaffe RB: Human placental vascular development: Vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. J Clin Endocrinol Metab 2002; 87: 4213-24.
12. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY et al.: Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998; 95: 8795-800.
13. Helmlinger G, Endo M, Ferrara N, Hlatky L, Jain RK: Formation of endothelial cell networks. Nature 2000; 405: 139-41.
14. Kingdom J, Huppertz B, Seaward G, Kaufmann P: Development of the placental villous tree and its consequences for fetal growth. Eur J Obstet Gynecol Reprod Biol 2000; 92: 35-43.
15. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF et al.: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-83.
16. Luttun A, Carmeliet P:TSoluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest 2003; 111: 600-2.
17. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S et al.: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-58.
18. Molskness TA, Stouffer RL, Burry KA, Gorrill MJ, Lee DM, Patton PE: Circulating levels of free and total vascular endothelial growth factor (VEGF)-A, soluble VEGF receptors-1 and -2, and angiogenin during ovarian stimulation in non-human primates and women. Hum Reprod 2004; 19: 822-30.
19. Mueller MD, Vigne JL, Minchenko A, Lebovic DI, Leitman DC, Taylor RN: Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc Natl Acad Sci USA 2000; 97: 10972-7.
20. Powers RW, Roberts JM, Cooper KM, Gallaher MJ, Frank MP, Harger GF et al.: Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol 2005; 193: 185-91.
21. Roberts JM: Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998; 16: 5-15.
22. Roeckl W, Hecht D, Sztajer H, Waltenberger J, Yayon A, Weich HA: Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp Cell Res 1998; 241: 161-70.
23. Santolaya-Forgas J, Romero R, Mehendale R: The effect of continuous morphine administration on maternal plasma oxytocin concentration and uterine contractions after open fetal surgery. J Matern Fetal Neonatal Med 2006; 19: 231-8.
24. Santolaya-Forgas J, Romero R, Wildman D, Kim CJ, Mahoney M, Mehendale R, and Burd L: Relationship between maternal and fetal plasma glucose and insulin concentrations during graded maternal hyperglycemic states in primates. Am J Perinatol 2006; 23: 369-75.
25. Sharkey AM, Charnock-Jones DS, Boocock CA, Brown KD, Smith SK: Expression of mRNA for vascular endothelial growth factor in human placenta. J Reprod Fertil 1993; 99: 609-15.
26. Springer ML, Chen AS, Kraft PE, Bednarski M, Blau HM: VEGF gene delivery to muscle: Potential role for vasculogenesis in adults. Mol Cell 1998; 2: 549-58.
27. Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR: Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2005; 122: 33-9.
28. Wong AK, Alfert M, Castrillon DH, Shen Q, Holash J, Yancopoulos GD et al.: Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome. Proc Natl Acad Sci USA 2001; 98: 7481-6.
29. Wulff C, Wilson H, Dickson SE, Wiegand SJ, Fraser HM: Hemochorial placentation in the primate: Expression of vascular endothelial growth factor, angiopoietins, and their receptors throughout pregnancy. Biol Reprod 2002; 66: 802-12.
30. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.